Elevated Osteopontin Levels in Mild Cognitive Impairment and Alzheimer’s Disease

Table 1

Clinical details and laboratory findings of HC, OND, MCI, and AD patients.

	HC	OND	MCInc	MCIc	ADn	ADc
Individuals, no.	20	20	18	13	17	18
Gender, no. of female/male	10/10	11/9	8/10	9/4	11/6	8/10
Mean age (mean ± SD)	72 (57–81)	71 (58–82)	73 (59–83)	72 (60–82)	73 (61–81)	74 (59–83)
MMSE score; (mean ± SD)	29 ± 1.5	28 ± 1.7	27.1 ± 1.4	27.9 ± 1.6	22.9 ± 2.7	18.9 ± 4.3
OPN plasma levels (ng/mL); (mean ± SD)	51.4 ± 9.8	53.3 ± 10.3	52.3 ± 11.7	53.7 ± 11.1	74.4±13.7	54.8 ± 10.1
OPN CSF levels; (mean ± SD)	—	134.5 ± 19.3	128.6 ± 17.7	173.2 ± 20.6	226.5 ± 21.2	165.6 ± 20.4
A𝛽 CSF levels (pg/mL); (mean ± SD)	—	326.7 ± 45.8	361.2 ± 48.1	181.7 ± 32.6	167.8 ± 26.9	196.3 ± 29.6
Tau CSF levels (pg/mL); (mean ± SD)	—	112 ± 21.6	141 ± 25.8	243.7 ± 31.6	275.4 ± 34.9	289.6 ± 38.9

HC: healthy control; OND: non-inflammatory neurologic diseases; MCInc: MCI non-converters; MCIc: MCI converters; Adn: newly diagnosed AD; ADc: chronical AD; OPN: osteopontin; SD: standard deviation.